OBJECTIVES: Analysis of pharmacoeconomic studies (FES), held in the Republic of Kazakhstan between 2005 and 2010. METHODS: Produced an information search using keywords «pharmacoeconomics», «clinical and economic analysis». It was analyzed 81 scientific researches of national researchers which was published in the republican (national) publications. RESULTS: Among the papers was dominated pharmacoeconomic studies (FES) in the therapeutic (bronchial asthma, COPD, hypertension, peptic ulcer, etc.) and psychiatric practice (mostly - Pharmacoeconomics of neuroleptics). Studies of the clinical and economic aspects for health technology assessments are not found. Selection of FES carried proactive. Among the methods of pharacoeconomic analysis (FEA) the most frequently used analysis was «cost of disease». Cost-effectiveness analysis was used in 23 (28%) studies. Incremental analysis was performed only in 2 FES. Analysis of the «cost minimization» was used methodologically correct only in 2 papers. Modeling in the FES was used in 10 (12%) studies. Another 6 (0.7%) works extrapolated the results of foreign researchers, taking into account the national clinical practice. Others were presented reviews of popularization of pharmacoeconomics, ABC and VEN-analysis of various medical organizations. CONCLUSIONS:  In Republic of Kazakhstan pharmacoecnomics is at an early stage of development. There is a need to update and deploy the FES on the background of the proper use the methodology of pharmacoeconomics, the definition of a coordinator and a real consumer FES, improvement of legislation provision for such research.